Ysios Capital

Ysios Capital is a Barcelona-based life sciences investor regarded as one of the more established European specialists focused on biotech and pharmaceuticals. The firm backs company creation around academic research and supports therapeutic platforms addressing high unmet medical need, often participating in syndicates alongside larger international biotech investors. There is no marketed artificial intelligence thesis; the focus is on biology and clinical development. Limited public information is available about individually named partners working on specific deals beyond the firm’s general team disclosures, although Ysios is well known within the European life sciences community.

Ysios invests from Seed through Series C, with check sizes typically in the five to twenty-five million dollar range, consistent with the capital intensity of biotech and pharma. Geographic concentration is Spain and the broader European life sciences ecosystem, with regular co-investment alongside global biotech specialists. The firm leads or co-leads founding rounds in newco structures and continues to participate in follow-on financings, reflecting a long-duration approach to therapeutic asset development across preclinical and clinical milestones.

For founders and academic teams, Ysios is most relevant when building a therapeutic company around defensible biology, strong intellectual property, and a credible clinical development plan. Engagement typically begins through scientific advisors, technology transfer offices, or co-investors already known to the firm. Diligence is rigorous on target validation, mechanism, regulatory pathway, and team composition, and the firm is comfortable working with first-time scientific founders provided experienced operators or chief executives can be brought in. Expect a partnership oriented toward clinical inflection points and exits aligned with strategic acquirers in the global pharmaceutical industry.